Klacid I.V. (Clarithromycin)

Clarithromycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, blocking the translocation step of peptide chain elongation. This bacteriostatic action stops bacterial growth and allows the host immune system to clear the infection.

The dosing regimen for Klacid I.V. is determined by the prescribing clinician based on the infection type, severity, patient weight, renal and hepatic function, and other clinical factors. Specific dosage information should be obtained from the treating physician.

Clarithromycin is classified as Pregnancy Category B, indicating that animal studies have not shown risk to the fetus and there are no adequate human studies. It may be used during pregnancy only if the potential benefit justifies the potential risk. Use while breastfeeding should be discussed with a healthcare professional.

To order Klacid I.V., submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details (including any cold‑chain requirements) and import documentation.

Klacid I.V. (clarithromycin) offers a broader spectrum against certain Gram‑negative organisms and better tissue penetration compared with older macrolides such as erythromycin. It also has a more favorable dosing schedule for intravenous use, though drug‑interaction and QT‑prolongation risks are similar across the class.

Klacid I.V. should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen. Before administration, the solution should be inspected for particulate matter and discoloration, and used within the time frame recommended by the manufacturer after reconstitution.

Klacid I.V. is administered by slow intravenous infusion under the supervision of a qualified healthcare professional. The infusion rate and duration are set by the prescriber according to the patient’s clinical condition and the specific infection being treated.

Serious risks include severe allergic reactions such as anaphylaxis, QT interval prolongation that can lead to life‑threatening arrhythmias, and Clostridioides difficile‑associated colitis. Patients should be monitored for signs of rash, cardiac symptoms, or persistent diarrhea, and the drug should be discontinued if these occur.

Klacid I.V. should be avoided in patients with a known hypersensitivity to clarithromycin or other macrolides, those with a history of significant QT prolongation, and individuals taking contraindicated medications such as cisapride or pimozide. Caution is also advised for patients with severe hepatic impairment.